The William K. Warren Foundation

Researchers at the Warren Center for Neuroscience Drug Discovery, a clinical stage biotech within the Vanderbilt University School of Medicine Basic Sciences, have detailed the successful drug discovery of a Phase I Single Ascending Dose clinical trial of VU319, a drug for memory loss in people with Alzheimer’s disease and schizophrenia. Read More